-
Mashup Score: 3National Kidney Month – Speaking with Your Doctor about CKD - 2 month(s) ago
March is National Kidney Month—a time to raise awareness about the importance of kidney health. Chronic Kidney Disease (CKD) affects an estimated 37 million Americans, and it is often referred to as a “silent disease” because there are usually no symptoms during its early stages. In fact, as many as 90% of Americans who have chronic kidney disease (CKD) don’t know they have it until it is very advanced. The kidneys play an important role in helping our bodies function properly. When the kidneys are
Source: www.astrazeneca-us.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 0National Kidney Month – Speaking with Your Doctor about CKD - 2 month(s) ago
March is National Kidney Month—a time to raise awareness about the importance of kidney health. Chronic Kidney Disease (CKD) affects an estimated 37 million Americans, and it is often referred to as a “silent disease” because there are usually no symptoms during its early stages. In fact, as many as 90% of Americans who have chronic kidney disease (CKD) don’t know they have it until it is very advanced. The kidneys play an important role in helping our bodies function properly. When the kidneys are
Source: www.astrazeneca-us.comCategories: General Medicine News, PayerTweet-
It’s #NationalKidneyMonth. Did you know that earlier detection of #ChronicKidneyDisease (CKD) can improve patient outcomes, limiting the impact on health systems, caregivers, economies and the environment? Learn more about #CKD management and our promise: https://t.co/hgHUNfOgHm https://t.co/VLjPy9yaj1
-
-
Mashup Score: 0That's Understandable - 2 month(s) ago
You are now leaving AstraZeneca-us.com You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents. AstraZeneca provides this link as a service to website visitors. AstraZeneca is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit. Click ‘cancel’ to return to AstraZeneca’s site or ‘continue’ to proceed. Important notice for users You are about to access
Source: www.astrazeneca-us.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 4
If approved, AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan may be the first TROP2-directed antibody drug conjugate for patients with lung cancer AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the US for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) who have received prior systemic therapy. The Prescription Drug User Fee Act date, the Food and Drug
Source: www.astrazeneca-us.comCategories: General Medicine News, PayerTweet-
In collaboration with @DaiichiSankyoUS, we announced the @US_FDA has accepted a Biologics License Application for our potential treatment for adult patients with previously treated advanced or metastatic nonsquamous non-small cell #lungcancer #NSCLC https://t.co/SPdMyRG4cb #AZUS https://t.co/RHqF5NmzAt
-
-
Mashup Score: 39
Positive high-level results from the LAURA Phase III trial showed AstraZeneca’s TAGRISSO ® (osimertinib) demonstrated a statistically significant and highly clinically meaningful improvement in progression-free survival (PFS) for patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after chemoradiotherapy (CRT) compared to placebo after CRT. Overall survival (OS) data showed a favorable trend for TAGRISSO, although data were not mature
Source: www.astrazeneca-us.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 3Our Commitment to Transforming Care in Cardiovascular Disease - 3 month(s) ago
Cardiovascular (CV) disease affects nearly 50 percent of adults in the United States and is the leading cause of death worldwide. Risk factors of heart disease include high blood pressure, high cholesterol, smoking, diabetes, unhealthy diet, excessive alcohol consumption and physical inactivity. [1][2] There are many CV diseases that affect the heart in various ways and can progress into more serious CV events. For example, coronary artery disease (CAD), which is plaque buildup in the arteries, can lead
Source: www.astrazeneca-us.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 11AstraZeneca expands US manufacturing footprint to accelerate ambitions in next-generation cell therapy discovery and development - 3 month(s) ago
New fa cility in Rockville, Maryland will focus on manufacturing for critical cancer trials and launch of its commercial cell therapy platforms AstraZeneca is investing $300 million in a state-of-the-art facility in Rockville, MD to launch its life-saving cell therapy platforms in the US for critical cancer trials and future commercial supply. More than 150 new highly skilled jobs will be created to initially focus on manufacturing T-cell therapies to enable clinical trials to be conducted around the
Source: www.astrazeneca-us.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 2ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with metastatic HER2-positive solid tumors - 3 month(s) ago
If approved, AstraZeneca and Daiichi Sankyo’s ENHERTU will potentially be the first HER2-directed treatment and antibody drug conjugate to receive a tumor-agnostic indication AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for ENHERTU ® (fam-trastuzumab deruxtecan-nxki) has been accepted and granted Priority Review in the US for the treatment of adult patients with unresectable or metastatic HER2-positive (immunohistochemistry [IHC] 3+) solid tumors who have received
Source: www.astrazeneca-us.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 8AIRSUPRA® (albuterol/budesonide) now available as the first and only FDA-approved anti-inflammatory rescue option for asthma - 4 month(s) ago
AstraZeneca announces AIRSUPRA ® (albuterol/budesonide), is now commercially available in the US by prescription. AIRSUPRA received FDA approval in January 2023 for the as-needed treatment or prevention of symptoms of asthma and to help prevent sudden severe breathing problems (asthma attacks) in people aged 18 years and older. 1 AIRSUPRA contains a short-acting beta 2 -agonist (SABA), to help relax the smooth muscles of the airways, and an inhaled corticosteroid (ICS), to help decrease inflammation in
Source: www.astrazeneca-us.comCategories: General Medicine News, Allergy-ImmunologyTweet
-
Mashup Score: 7
Positive results from the EMERALD-1 Phase III trial showed AstraZeneca’s IMFINZI ® (durvalumab) in combination with TACE and bevacizumab demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival (PFS) compared to TACE alone in patients with hepatocellular carcinoma (HCC) eligible for embolization. These results will be presented today at the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) in
Source: www.astrazeneca-us.comCategories: General Medicine News, PayerTweet
#DidYouKnow that early detection is key to slowing the progression of chronic kidney disease (CKD)? This #NationalKidneyMonth and #WorldKidneyDay, speak to your doctor about #CKD risk factors and develop a management plan that’s right for you. Learn more: https://t.co/Yxo3Z5UeJA https://t.co/9Xoh68AVyj